Tolerability of Abiraterone (abi) Combined with Olaparib (ola) in Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (mcrpc): Further Results from the Phase III PROpel Trial.Antoine Thiery-Vuillemin,Fred Saad,Andrew J. Armstrong,Mototsugu Oya, Karina Costa Maia Vianna,Mustafa Ozguroglu,Craig Gedye,Gary L. Buchschacher,Ji Youl Lee,Urban Emmenegger,Jiri Navratil,Juan Antonio Virizuela,Anibal Salazar,Denis Maillet,Hiroji Uemura,Jeri Kim,Edit Lukacs,Laura Barker,Arnold N. Degboe,Noel W. ClarkeJournal of clinical oncology（2022）引用 1|浏览30暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
